Pieter H. Reitsma
Keine laufenden Positionen mehr
Karriereverlauf von Pieter H. Reitsma
Ehemalige bekannte Positionen von Pieter H. Reitsma
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Varmx BV
 Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Technik-/Wissenschafts-/F&E-Leiter | - | 08.03.2023 |
| Gründer | - | 08.03.2023 |
Statistik
International
| Niederlande | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sektoral
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Varmx BV
Varmx BV BiotechnologyHealth Technology VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018. | Health Technology |
- Börse
- Insiders
- Pieter H. Reitsma
- Erfahrung
